Inhibition of adipose tissue lipolysis increases intramuscular lipid and glycogen use in vivo in humans

This study investigates the consequences of inhibition of adipose tissue lipolysis on skeletal muscle substrate use. Ten subjects were studied at rest and during exercise and subsequent recovery under normal, fasting conditions ( control trial, CON) and following administration of a nicotinic acid analog ( low plasma free fatty acid trial, LFA). Continuous [ U-C-13] palmitate and [ 6,6- H-2(2)] glucose infusions were applied to quantify plasma free fatty acid ( FFA) and glucose oxidation rates and to estimate intramuscular triacylglycerol ( IMTG) and glycogen use. Muscle biopsies were collected to measure 1) fiber type- specific IMTG content; 2) allosteric regulators of hormone- sensitive lipase ( HSL), glycogen phosphorylase, and pyruvate dehydrogenase; and 3) the phosphorylation status of HSL at Ser(563) and Ser(565). Administration of a nicotinic acid analog ( acipimox) substantially reduced plasma FFA rate of appearance and subsequent plasma FFA concentrations ( P < 0.0001). At rest, this substantially reduced plasma FFA oxidation rates, which was compensated by an increase in the estimated IMTG use ( P < 0.05). During exercise, the progressive increase in FFA rate of appearance, uptake, and oxidation was prevented in the LFA trial and matched by greater IMTG and glycogen use. Differential phosphorylation of HSL or relief of its allosteric inhibition by long- chain fatty acyl- CoA could not explain the increase in muscle TG use, but there was evidence to support the contention that regulation may reside at the level of the glucose- fatty acid cycle. This study confirms the hypothesis that plasma FFA availability regulates both intramuscular lipid and glycogen use in vivo in humans.